Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind study of HY-0902 versus febuxostat in gout with hyperuricemia and tophus dissolution
CTR20262579Phase 2Active
- Sponsor
- Shandong Haiya Pharmaceutical Technology
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HY-0902 in gout, hyperuricemia, sponsored by Shandong Haiya Pharmaceutical Technology. Started Aug 2026; status: active.
02
Drugs
HY-0902
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20262579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262579.